BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd
August 27 2024 - 11:35AM
BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in
genomic diagnostics and personalized medicine, is pleased to
announce the successful co-investment by the Securities Commission
of Malaysia under its Malaysia Co-Investment Fund (MyCIF), into
Ascension Innovation Sdn Bhd (AISB). This co-investment, alongside
BGLC's recent investment, the first under its Environmental &
Social Impact (ESI) Scheme shows confidence in the strategic
direction and potential of AISB.
AISB, a pioneering healthcare technology company, has become the
first issuer to receive investment under the Environmental &
Social Impact (ESI) scheme, part of the broader MyCIF initiative.
This scheme, designed to support small and medium enterprises
(MSMEs) with impactful solutions, aligns perfectly with AISB’s
mission to revolutionize healthcare through innovative, sustainable
practices.
Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp.,
commented, “We are honored to have the Securities Commission
Malaysia through it’s MyCIF Fund, co-invest in Ascension Innovation
Sdn Bhd. This collaboration is not only a testament to the robust
potential of AISB’s technology but also reflects the confidence in
our strategic investment decisions. The support from MyCIF will
significantly bolster AISB's efforts to advance the ‘One Patient,
One Record’ initiative under Malaysia's National Electronic Medical
Records (EMR) Plan, a critical step towards modernizing the
nation’s healthcare infrastructure.”
The co-investment will empower AISB to accelerate the deployment
of its AI-driven healthcare solutions, particularly through its
flagship platform, aiCMS. This platform is designed to integrate
predictive analytics and generative AI to enhance clinical
management and patient care across Malaysia.
“This investment partnership represents a milestone in our
collective vision to create a more sustainable, efficient
healthcare system,” said Andrew Teng, CEO of Ascension Innovation
Sdn Bhd. “We are committed to leveraging this support to achieve
our goals and contribute meaningfully to Malaysia's healthcare
transformation.”
The MyCIF investment is a significant milestone for AISB and
BGLC, reflecting the growing importance of sustainable and
impactful healthcare innovations in the digital age, bringing the
total investment in this round to RM1.7 million (approx. USD
390k).
About BioNexus Gene Lab Corp.BioNexus Gene Lab
Corp. (NASDAQ: BGLC) is an emerging leader in RNA-based genomic
diagnostics, committed to advancing personalized medicine and
improving global health outcomes.
For more information, visit www.bionexusgenelab.com.
About Ascension Innovation Sdn BhdAscension
Innovation Sdn Bhd is a leading healthcare technology company
focused on innovative AI-driven solutions. Visit www.aisb.io for
more details.
Investor RelationsBioNexus Gene Lab CorporationEmail:
ir@bionexusgenelab.com
BioNexus Gene Lab (NASDAQ:BGLC)
Historical Stock Chart
From Jul 2024 to Aug 2024
BioNexus Gene Lab (NASDAQ:BGLC)
Historical Stock Chart
From Aug 2023 to Aug 2024